Literature DB >> 11124064

Perfluorochemical liquid enhances adeno-associated virus-mediated transgene expression in lungs.

D J Weiss1, L Bonneau, J M Allen, A D Miller, C L Halbert.   

Abstract

Use of adeno-associated virus (AAV) vectors for lung gene therapy is limited, in part, by low levels of AAV-mediated transgene expression in lungs. Generally, less than 1% of total airway and alveolar epithelial cells express transgene activity following vector administration. A means of improving AAV vector delivery could potentially enhance AAV-mediated gene expression in lungs. We have previously demonstrated that use of perfluorochemical (PFC) liquids improved overall levels of adenovirus vector-mediated gene expression as well as distribution of expression in lungs of spontaneously breathing rodents. To evaluate whether use of PFC liquids might similarly enhance AAV-mediated expression, spontaneously breathing rodents received intratracheal instillation of the AAV vectors CWRAP and ARAP4 (2-5 x 10(8) FFU/animal) with or without 10 cc/kg body wt PFC liquid (FC-75, ACROS). Animals were sacrificed 4 weeks later and lungs assessed for overall and in situ alkaline phosphatase (AP) expression. Animals receiving vector alone exhibited scattered sparse in situ activity, predominantly in alveolar epithelium. In contrast, animals receiving vector with FC-75 exhibited increased and more widespread AP expression as well as up to a 26-fold increase in AP activity. These results demonstrate that use of the PFC liquid FC-75 improves overall and in situ AAV-mediated gene expression in rodent lungs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124064     DOI: 10.1006/mthe.2000.0207

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

Review 1.  Effective viral-mediated lung gene therapy: is airway surface preparation necessary?

Authors:  David Parsons; Martin Donnelley; Alexandra McCarron; Patricia Cmielewski; Victoria Drysdale
Journal:  Gene Ther       Date:  2022-03-29       Impact factor: 4.184

Review 2.  Administration of Drugs/Gene Products to the Respiratory System: A Historical Perspective of the Use of Inert Liquids.

Authors:  Deepthi Alapati; Thomas H Shaffer
Journal:  Front Physiol       Date:  2022-05-10       Impact factor: 4.755

3.  Inhalation of nebulized perfluorochemical enhances recombinant adenovirus and adeno-associated virus-mediated gene expression in lung epithelium.

Authors:  Travis Beckett; Laura Bonneau; Alan Howard; James Blanchard; Juan Borda; Daniel J Weiner; Lili Wang; Guang Ping Gao; Jay K Kolls; Rudolf Bohm; Denny Liggitt; Daniel J Weiss
Journal:  Hum Gene Ther Methods       Date:  2012-05-08       Impact factor: 2.396

Review 4.  Current status of gene therapy for inherited lung diseases.

Authors:  Ryan A Driskell; John F Engelhardt
Journal:  Annu Rev Physiol       Date:  2002-05-01       Impact factor: 19.318

Review 5.  Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.

Authors:  Stefano Ferrari; Duncan M Geddes; Eric W F W Alton
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

6.  Perfluorochemical (PFC) liquid enhances recombinant adenovirus vector-mediated viral interleukin-10 (AdvIL-10) expression in rodent lung.

Authors:  John T Li; Laura A Bonneau; Jerry J Zimmerman; Daniel J Weiss
Journal:  J Inflamm (Lond)       Date:  2007-05-01       Impact factor: 4.981

Review 7.  Delivery systems for pulmonary gene therapy.

Authors:  Ajay Gautam; Clifford J Waldrep; Charles L Densmore
Journal:  Am J Respir Med       Date:  2002

Review 8.  Gene therapy progress and prospects: cystic fibrosis.

Authors:  U Griesenbach; S Ferrari; D M Geddes; E W F W Alton
Journal:  Gene Ther       Date:  2002-10       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.